Neuroendocrine Tumor Treatment Market Surpass $4.2 Billion By 2026: Acumen Research and Consulting

Author: Acumen Research and Consulting

According to newly published report by Acumen Research and Consulting, titled 'Neuroendocrine Tumor Treatment Market (By Product: Somatostatin Analogs (SSAs), Targeted Therapy, Others; By Site: Lungs, Pancreas, Colon, Small Intestine, Others; By End-user: Hospitals, Clinics, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026'. The global NET treatment market size is anticipated to around USD 4.2 billion by 2026, this market is anticipated to grow with 10.1% CAGR during the forecast time period. Growing cases of neuroendocrine tumors (NETs) are anticipated to drive the need for treatment options, thus increasing the market development over the forecasted time frame. This is a speedily progressing field as the novel therapies and analytic products are being developed.

North America captures for the highest market share in 2018 due to supportive insurance policies in the respective region facilitating NET treatment, for instance, Tricare, Medicare, and Medicaid. Furthermore, sophisticated healthcare facilities and high research and development expenditure by pharmaceutical businesses and regional government for cancer research are other factors driving the North America NET treatment market.

Download Report Sample Pages For Better Understanding@ 

Asia Pacific NET treatment market is expected to observer important development in the coming years owing to increasing occurrence of NETs in the respective region. Growing investments by the regional governments to tackle the high unmet clinical needs are also expected to aid surge the market development.

Few of the ongoing clinical trials comprise of RAD 001 to treat progressive midgut NETs, NET-01 chemotherapy for pancreatic tumors, and LanreotideAutogel for non-functional tumors. Continuing research and development activities in detection methods, for instance,radio frequency ablation technique, and Ga labeledradionucleotide therapies are the main factors boosting the need NET treatment market.


The global NET treatment market is segmented into product, site, end-user and region.On the basis of product, the global NET treatment market is segmented into somatostatin analogs (ssas), targeted therapy, and others. On the basis of site,the global NET treatment market is segmented into lungs, pancreas, colon, small intestine, and others. On the basis of the end-user, the global NET treatment market is segmented into hospitals, clinics, and others.On the basis of region the global NET treatment market is segmented into Latin America, Europe, Asia Pacific, North America, and Middle East & Africa.

Europe captured the market share more than 20.5% of the global market share during the forecast period. Greater extent of public funding in Europe’s healthcare system has backed to this development. Furthermore, occurrence of target populace base paired with government support to control cancer captures to significant development of this region. Such as, formation of bodies, for instance, the European Cancer Observatory, produced consciousness about cancer.Asia Pacific is anticipated to observer profitable development forthcoming due to helpful government initiatives and improving healthcare infrastructure. Furthermore, economic growths in countries, for instance, China and India, are anticipated to aid drive the market development. Enormous populace base with low per capita income in the region captures to high need for reasonable treatment options.

North America captures the major market share in 2018 accounting for over 34.6% of its share and is projected to continue its dominance during the forthcoming. Main parameter contributing to development of this region comprise government support for high purchasing power parity, quality healthcare, availability of reimbursement, and growing occurrence of cancers in Canada and U.S.

Such as, in U.S., the (PPACA) Patient Protection and Affordable Care Act, also called as Obama Care, encourages quality and affordability of health insurance and decreases the cost of healthcare for individuals and government. Government initiatives, such as, Precision Medicine Initiative formulating tailored tactics on unique features of diseases, are aiding in improving the overall healthcare system, there fore increasing market development.

Multinational businesses are looking forward to capitalising in the emerging nations of Asia Pacific. Therefore, numerousintegration partnerships and planned associations are taking place with businesses in this region. All these parameters is expected to spur the market development.

Market companies are concentrating on implementing new strategies for instance regional expansion, partnerships, mergers and acquisitions, new product launches, and distribution agreements to surge their revenue share. And also, growing R&D investments paired with technical advancements to commercialize highly efficient products are expected to offer huge growth opportunities for industry participants. Some of the main businesses present in theNET treatment market are BoehringerIngelheim International GmbH, AVEO Oncology, Hutchison MediPharma Limited, Novartis AG, IpsenPharma,Pfizer, Inc., and Progenics Pharmaceuticals.Significant strategic initiatives undertaken by global businesses include partnerships, new product launch, acquisitions.


The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report - 

Would like to place an order or any question, please feel free to contact at | +1 407 915 4157